Loading...
•
Dec 31, 2023
Marinus Pharmaceuticals Q4 2023 Earnings Report
Marinus Pharmaceuticals reported Q4 2023 financial results and provided a business update.
Key Takeaways
Marinus Pharmaceuticals reported ZTALMY net product revenue of $6.6 million for Q4 2023 and expects full year 2024 U.S. ZTALMY net product revenues of between $32 and $34 million. The company's cash runway is projected into Q4 2024, with cash, cash equivalents, and short-term investments of $150.3 million as of December 31, 2023.
Phase 3 RAISE trial interim analysis enrollment target achieved; topline results expected in the first half of Q2 2024.
Phase 3 TrustTSC trial approximately 85% enrolled; topline data now expected in the first half of Q4 2024.
ZTALMY net product revenue reached $6.6 million for Q4 2023 and $19.6 million for the full year.
Cash runway projected into Q4 2024 with $150.3 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
Revenue by Segment
Forward Guidance
Marinus Pharmaceuticals anticipates ZTALMY U.S. net product revenues of between $32 and $34 million for the fiscal year 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...